Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TRUQAP | AstraZeneca | N-218197 RX | 2023-11-16 | 2 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
truqap | New Drug Application | 2023-11-16 |
Expiration | Code | ||
---|---|---|---|
CAPIVASERTIB, TRUQAP, ASTRAZENECA | |||
2028-11-16 | NCE |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 8 | 11 | 2 | — | — | 17 |
Prostatic neoplasms | D011471 | — | C61 | 3 | 4 | 1 | — | — | 7 |
Triple negative breast neoplasms | D064726 | — | — | 2 | 3 | 1 | — | — | 4 |
Castration-resistant prostatic neoplasms | D064129 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 4 | 1 | — | — | — | 5 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | 2 | — | — | — | 4 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | 1 | — | — | — | 3 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 2 | — | — | — | 2 |
Adenocarcinoma | D000230 | — | — | — | 2 | — | — | — | 2 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 2 | — | — | — | 2 |
Multiple myeloma | D009101 | — | C90.0 | — | 2 | — | — | — | 2 |
Lymphoma | D008223 | — | C85.9 | — | 2 | — | — | — | 2 |
Melanoma | D008545 | — | — | 1 | 1 | — | — | — | 2 |
Uterine cervical neoplasms | D002583 | HP_0030159 | — | 1 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | — | — | — | 1 |
Chondrosarcoma | D002813 | — | — | 1 | — | — | — | — | 1 |
Acinar cell carcinoma | D018267 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Capivasertib |
INN | capivasertib |
Description | Capivasertib is an aminopiperidine that is piperidine substituted by 7H-pyrrolo[2,3-d]pyrimidin-4-yl, amino, and [(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]aminocarbonyl groups at positions 1, 4, and 4, respectively. It is a pan-AKT kinase inhibitor used in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations. It has a role as an antineoplastic agent and an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor. It is a pyrrolopyrimidine, an aminopiperidine, a piperidinecarboxamide, a member of monochlorobenzenes, a primary alcohol and a secondary carboxamide. |
Classification | Small molecule |
Drug class | serine/threonine kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2nc[nH]c3nccc2-3)CC1 |
PDB | — |
CAS-ID | 1143532-39-1 |
RxCUI | — |
ChEMBL ID | CHEMBL2325741 |
ChEBI ID | — |
PubChem CID | 25227436 |
DrugBank | DB12218 |
UNII ID | WFR23M21IE (ChemIDplus, GSRS) |